Radioisotope Therapy vs External Beam Radiation — When Each Is Used

External beam radiation is aimed at the cancer from a machine outside your body, one region at a time. Radioisotope therapy is a radioactive substance given as an injection, infusion or capsule; it travels in your bloodstream and settles where the cancer is. One treats a place you can point to on a scan. The other reaches disease wherever it has already gone.

That is the whole distinction, and it is worth holding on to, because it is the single point that gets lost most often in an advanced-disease consultation. Two doctors can both say “radiation” in the same appointment and mean two completely different things. The radiation oncologist usually means a beam. The nuclear medicine physician usually means a radioactive carrier given into a vein.

Neither is a newer version of the other. They are not ranked. They answer different questions about your disease, and which question your team is trying to answer is what decides between them.

Both are coordinated, not owned, by CION. Your external beam radiotherapy is delivered at an NABH-accredited partner centre and radioisotope therapy at a licensed partner nuclear-medicine facility; CION Cancer Clinics coordinates your treatment plan, your oncology team and your care throughout. CION does not own or operate a linear accelerator, a CyberKnife, a Gamma Knife or a nuclear medicine hot lab.

The sections below cover how your team decides between them, a side-by-side comparison you can take into your own consult, and what happens when both are part of the same plan.

External beam radiation is chosen when the disease sits in one place, or a small number of places, that can be mapped on a scan and aimed at precisely. Radioisotope therapy is considered when disease is in many places at once, or when the cancer carries a target that a radioactive carrier can seek out on its own.

In line with NCCN and ASTRO guidance, the decision turns on the cancer type, where the disease actually is, what has already been given, and how well your kidneys, liver and blood counts are holding up. It is a tumour board decision. It is not a menu you choose from.

Often, yes. They are not alternatives you must pick between once and for all. A common pattern is external beam radiation to one site that is painful or at risk of fracture, with radioisotope therapy for disease that has spread more widely — given in a planned sequence rather than at random.

What matters is the order and the spacing. Radioisotope therapy can lower blood counts, and so can external beam radiation when a large volume of marrow-bearing bone sits inside the treated area. Giving both to overlapping regions at the same time can push counts down further than either would alone, which is why teams usually stagger them and check a blood count in between.

There is a second, practical reason to plan them together: eligibility for radioisotope therapy is confirmed by a scan, and that scan needs to be read against the whole picture, not just the site being irradiated. If two teams plan separately, the sequence can end up decided by whoever booked first.

So the thing to ask for is not permission. It is a single conversation. Have my radiation oncologist and my nuclear medicine physician agreed the order between them? If the answer is no, that is the meeting worth requesting before anything starts.

It is carried, not aimed. The radioactive atom is attached to something the body already handles in a predictable way — a mineral that goes to repairing bone, or a molecule that locks on to a marker sitting on the surface of the cancer cell. Where that carrier goes, the radiation goes with it.

This is why the scan comes first. Before treatment, an imaging test using a small, non-treating dose of the same kind of carrier is used to see whether your cancer actually picks it up. If the scan lights up at the disease sites, the target exists. If it does not, the treatment is unlikely to be offered, no matter how advanced the disease is.

That pairing — a scan that finds the target and a treatment that uses the same route — is what the word theranostics describes. It is also the clearest practical difference from external beam radiation, where the scan is used to draw a shape for a machine to follow rather than to prove the cancer will take something up.

The radiation itself is short-range. It acts close to where the carrier lands and then decays. That is the point of the design: reach many places at once, but deposit the dose near the target rather than on the way through.

If radioisotope therapy is on the table for you, two sibling pages go further into the practical side — how many cycles of radioisotope therapy you are likely to need, and the side effects of Lu-177 and radioisotope therapy.

Indicative only, as of August 2026. A full course of external beam radiation in India commonly runs roughly ₹1.5 lakh to ₹6 lakh depending on the technique planned. Radioisotope therapy is priced per cycle and commonly runs roughly ₹3.5 lakh to ₹7 lakh a cycle, with most protocols involving more than one.

Those are planning ranges, not quotes. Two things are routinely left out of a first estimate: the scan that confirms eligibility, and the blood tests and reviews between cycles. If an isolation-room stay is part of your protocol, that is a separate line as well. Ask for an itemised written estimate covering the whole course, not the first dose.

Access differs too. External beam radiation is widely available across Telangana and Andhra Pradesh at NABH-accredited partner centres. Radioisotope therapy needs a licensed nuclear-medicine facility with the right approvals and shielded rooms, so it is offered at a smaller number of centres and slots can be scheduled weeks ahead. Our page on where radioisotope therapy is available in Hyderabad and South India covers that in detail.

Insurance handling also differs between the two, and cover for radioisotope therapy varies more widely between policies. Confirm your policy’s terms and the pre-authorisation process in writing before the first cycle rather than after it.

• Already told radioisotope therapy is an option and wondering how long the course runs? How Many Cycles of Radioisotope Therapy Will I Need? explains how cycles are spaced and what decides the number.
• Trying to find out where it is even offered? Where Radioisotope Therapy Is Available in Hyderabad and South India covers which facilities are licensed for it and how far ahead slots are booked.
• Weighing up what the treatment feels like afterwards? Side Effects of Lu-177 and Radioisotope Therapy sets out what is common, what settles and what needs a call.
• Dealing with pain in several bones at once rather than one site? Samarium and Strontium Injections for Widespread Bone Pain covers the bone-seeking route specifically.
• For the wider picture — how radiation techniques are chosen and coordinated with NABH-accredited partner centres — see Radiation Therapy at CION Cancer Clinics.

Still unsure which treatment you have actually been offered, or how the two would fit together in your case? Book a free consultation and a radiation oncologist will go through your reports with you directly.